SCM
FULC icon

Silverarc Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Silverarc Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Hold
391,900
– – 0.15% 66
2026
Q1 		$3.01M Hold
391,900
– – 0.31% 51
2025
Q4 		$4.43M Buy
+391,900
New +$3.99M 0.62% 43

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Silverarc Capital Management's FULC Position: Q2 2026 in Review

Silverarc Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 419,949 shares — an estimated $2.55M sold.

Silverarc Capital Management first reported a position in FULC in Q4 2020 and held it in 7 quarters. The position peaked at $5.24M in Q3 2021. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Silverarc Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 419,949 Fulcrum Therapeutics shares in Q2 2026, an estimated $2.55M.
  • Silverarc Capital Management first reported a position in Fulcrum Therapeutics in Q4 2020 and held it in 7 quarters.
  • Silverarc Capital Management's Fulcrum Therapeutics position peaked at $5.24M in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.